Collegium Pharmaceutical, Inc. announced that its Board of Directors has authorized a new share repurchase program, allowing the company to repurchase up to $150 million in common stock. This program is set to run through December 31, 2026. This new authorization replaces a previous $150 million share repurchase program that expired on June 30, 2025, which had $65 million remaining.
Colleen Tupper, Chief Financial Officer, stated that Collegium’s strong financial position provides significant flexibility in executing its capital allocation strategy. The new program reinforces the company's commitment to returning value to shareholders. Collegium has returned $222 million in value to shareholders under its share repurchase programs since 2021.
The company remains confident in its future growth trajectory and is committed to generating additional value by investing in key product growth drivers, diversifying its portfolio through disciplined business development, rapidly paying down debt, and opportunistically repurchasing shares. An accelerated share repurchase program initiated in May 2025 is expected to be completed in the third quarter of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.